ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)

ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)

From: GRACEcast
0 0 7 years ago
00:00
05:44
Medicine, #acquired, #alk, #alkpositive, #ap26113, #cancergrace, #ch5424802, #david, #dr, #edward, #garon, #geffen, #grace, #gracecast, #ldk378, #medicine, #of, #rearrangement, #resistance, #school, #ucla
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

Author

cancerGRACE Meetings
cancerGRACE Meetings 2 followers Follow

Find us on Facebook

Spreaker logo
  • Choose Language

For Podcasters and Editors

Tools for Podcasters

For Listeners

Copyright 2021 - Spreaker Inc. a Voxnest Company - Create a Podcast - New York, NY